News Release

Myriad Genetics to Present at the 2013 J.P. Morgan Annual Healthcare Conference

SALT LAKE CITY, Dec. 17, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, President and CEO, is scheduled to present at the 2013 J.P. Morgan Annual Healthcare Conference, at 9:30 a.m. Pacific Time on Monday, January 7, 2013. The conference is being held at the Westin St. Francis in San Francisco, California.

The presentation will be available to interested parties through a live webcast accessible on the investor relations section of Myriad's website at www.myriad.com.

About Myriad Genetics

Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad's portfolio of molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a commitment to improving an individual's decision making process for monitoring and treating disease. Myriad is focused on strategic directives to introduce new products, including companion diagnostics, as well as expanding internationally. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com

Myriad, the Myriad logo, BRACAnalysis, Colaris, Colaris AP, Melaris, TheraGuide, Prezeon, OnDose, Panexia and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries. MYGN-G

CONTACT: Investor Relations

         Jim Evans, Chief Financial Officer

         (801) 584-1143

         investors@myriad.com



         Media Relations

         Stephanie Ashe

         Continuum Health Communications

         sashe@continuumhealthcom.com

Source: Myriad Genetics, Inc.

News Provided by Acquire Media